Viyash Scientific, formerly known as Sequent Scientific, has set an ambitious goal to reach $1 billion in revenue and $250 million in EBITDA by 2032. This long-term target follows its successful merger, which has transformed the company into a vertically integrated pharmaceutical entity. Investors are watching how the company manages the integration of its human and animal health businesses alongside its expansion into high-growth segments like companion animal health and CDMO services.
What Happened
Viyash Scientific has announced a strategic long-term roadmap aiming to achieve $1 billion in annual revenue and $250 million in EBITDA by 2032. This announcement follows the company's recent operational integration, which combined the strengths of the former Sequent Scientific with Viyash Life Sciences. The company is now positioning itself as a vertically integrated pharmaceutical enterprise with a broad footprint across both human and animal health segments.
Business Transformation Post-Merger
The entity, formerly known as Sequent Scientific, completed its merger with Viyash Life Sciences in late 2025. This move has fundamentally changed the company’s structure. Previously focused heavily on animal health, the company now operates across a wider spectrum, including Active Pharmaceutical Ingredients (APIs), finished formulations, and Contract Development and Manufacturing Organization (CDMO) services. This integration allows the company to handle complex pharmaceutical products from development to manufacturing, aiming for higher margins compared to commodity-focused businesses.
Key Growth Drivers
Management has identified two primary pillars to achieve its 2032 revenue target. First, the Companion Animal (CA) segment is expected to become a major revenue driver, with specific aspirations to contribute between $150 million and $200 million. This segment is often viewed by the industry as having stable, non-cyclical demand.
Second, the company is aggressively expanding its CDMO business. By focusing on the "innovator life cycle management"—essentially helping other pharmaceutical companies manage their products—Viyash aims to secure high-value partnerships. The company’s pipeline currently involves multiple partners and projects, including several "first-to-file" opportunities. The company is also moving toward higher-value products to improve its overall profitability.
Risks and Monitorables
While the long-term targets are ambitious, the company faces several operational and market risks that investors should monitor.
Regulatory compliance remains a critical factor. As the company operates in highly regulated markets like the US and Europe, it is subject to audits by agencies such as the US FDA and EU GMP. Any adverse findings from these audits could impact operations and international revenue.
Financial risks include exposure to foreign exchange fluctuations, given that a significant portion of revenue is generated from export markets. Additionally, raw material price volatility can put pressure on profit margins.
Integration execution is another factor to watch. While the company has reported successful operational synergies post-merger, maintaining this efficiency as it scales its R&D and manufacturing capacity will be essential to meeting its 25% Return on Capital Employed (ROCE) target. Costs related to employee stock options (ESOPs) and other merger-related adjustments are also factors that may influence short-term earnings reports.
What Investors Should Track
Going forward, the key indicators for investors will be the realization of promised merger synergies and the growth of the companion animal segment. Market participants will likely watch for quarterly updates on EBITDA margins, as management has signaled a shift toward high-margin complex formulations. Tracking the pace of R&D investment and new project wins in the CDMO space will also provide insight into the company's progress toward its 2032 goal.